Innovation Signal 69 (2026) | 26 October 2026
Blood-forming stem cells are becoming easier to edit directly inside the body
Short note, about 5 minutes to read.
What happened
Editing blood-forming stem cells is not new. Some existing genetic treatments already remove a patient’s stem cells, modify them outside the body and return them to the patient.
That is beginning to change.
Researchers led by East China Normal University developed lipid nanoparticles that carry genetic-editing instructions to blood-forming stem cells. In humanised mice, the approach edited human stem cells in the bone marrow and produced changes intended to restore healthier blood-cell function.
Independently, researchers led by the Chinese Academy of Medical Sciences and Peking Union Medical College and the Chinese Academy of Sciences developed nanoparticles designed to target a marker found on human blood-forming stem cells (CD34). Using humanised mice, the researchers showed that the resulting genetic changes could persist during long-term observation.
Together, the results show that genome editing is becoming more capable of reaching and modifying blood-forming stem cells without first removing them from the body.
Why this matters
Some genetic treatments involving blood-forming stem cells require cells to be collected from a patient, modified in specialised facilities and then returned to the body.
That makes treatment complex and can require substantial clinical infrastructure.
If these cells can eventually be edited safely and reliably inside the body, some future treatments could reduce the need for parts of that process and make genetic medicine easier to deliver.
Who should care
- Genetic medicine and gene-editing companies
- Cell and gene therapy companies
- Haematology and transplant centres
- Pharmaceutical and biotechnology companies
- Healthcare systems developing advanced therapies
- Investors tracking emerging genetic medicines
What could change over the next 2 to 3 years
The next important evidence will be whether direct editing of blood-forming stem cells can move from animal models towards testing in people while maintaining precise targeting and durable editing.
Watch for larger preclinical studies, longer follow-up and the first clinical studies designed to test whether these approaches can edit enough stem cells safely inside the body.
What might block this
Reaching blood-forming stem cells inside the body does not by itself make an effective treatment.
The editing machinery must reach enough of the right cells while avoiding unwanted effects elsewhere. The genetic changes must also remain effective as edited stem cells continue producing new blood cells.
Most importantly, the recent results are preclinical. They do not yet show that directly editing blood-forming stem cells inside the body is safe or effective in people.
Why I am sharing this
Editing cells outside the body gives researchers substantial control over which cells are modified before they are returned to a patient. Editing those same cells while they remain inside the body is a much harder delivery problem.
Recent research suggests that delivery barrier is beginning to weaken.
The laboratory may not always need to be where the genetic editing happens.
If you found this useful, please consider forwarding it to someone who may also find it valuable.
Archive Tags
Genome Editing · Gene Therapy · Blood-Forming Stem Cells · In Vivo Editing